Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: glycans make the difference

dc.creatorCroci Russo, Diego Omar
dc.creatorRabinovich, Gabriel Adrian
dc.date.accessioned2016-09-12T20:11:30Z
dc.date.available2016-09-12T20:11:30Z
dc.date.created2016-09-12T20:11:30Z
dc.date.issued2014-06-25
dc.identifierCroci Russo, Diego Omar; Rabinovich, Gabriel Adrian; Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: glycans make the difference; Landes Bioscience; OncoImmunology; 3; 6; 25-6-2014; e29380-e29380
dc.identifier2162-4011
dc.identifierhttp://hdl.handle.net/11336/7610
dc.description.abstractAlthough blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-glycans on VEGFR2 links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in response to VEGF blockade.
dc.languageeng
dc.publisherLandes Bioscience
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.4161/onci.29380
dc.relationinfo:eu-repo/semantics/altIdentifier/url/www.tandfonline.com/doi/abs/10.4161/onci.29380
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGalectin 1
dc.subjectAngiogenesis
dc.subjectVegf
dc.subjectGlycans
dc.subjectCancer Immunotherapy
dc.titleLinking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: glycans make the difference
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución